Centre of Research Excellence - Personalising antimicrobial dosing to reduce resistance

Current research projects

CRE REDUCE PROJECTS
Therapeutic Drug Monitoring Group
Aims to robustly identify antimicrobial pharmacokinetic-pharmacodynamic (PK-PD) targets for use in clinical practice by better defining relationships between antimicrobial blood concentrations and outcomes.
Clinical Microsampling Group
Aims to replace traditional, highly invasive blood-taking techniques with an innovative microsampling approach that enables measuring drug concentrations in a drop of blood.
BLING III: A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients
National Health and Medical Research Council
Pharmacokinetics of antimicrobials in critically ill paediatric patients
National Health and Medical Research Council
The PNEUDOS Study Program: defining novel and individualised antimicrobial dosing regimens for treatment of pneumonia in ICU
National Health and Medical Research Council
Exploring the impact of altered and variable antimicrobial pharmacokinetics on bacterial killing and emergence of bacterial resistance.
National Health and Medical Research Council
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT).
National Health and Medical Research Council
Pharmacokinetics of Flucloxacillin and Lincomycin in burns patients.
National Health and Medical Research Council
Pharmacokinetics of antifungals in intensive care patients
National Health and Medical Research Council
Antimicrobial pharmacokinetics in patients with cystic fibrosis, lung and bone marrow transplant.
National Health and Medical Research Council
Pharmacokinetics of antimicrobials in critically ill obese patients
National Health and Medical Research Council
Pharmacometric analysis of antimicrobial pharmacokinetics to propose novel and innovative dosing regimens.
National Health and Medical Research Council
Therapeutic drug monitoring optimisation of antimicrobial exposures for critically ill, burns and transplant patients.
Continuous versus intermittent beta-lactams administration in critically ill patients with sepsis not receiving renal replacement therapy.
Therapeutic drug monitoring and dose personalisation of antimicrobials in mechanically ventilated patients with Gram-negative pneumonia.
Develop informed consumer groups whose members participate as partners in CRE research projects and processes
Development of clinical practice guidelines on antimicrobial dosing incorporating new knowledge generated by the CRE REDUCE.
PK/PD of antimicrobials in other 'at risk patient groups